- Home
- TPVG vs FENC Comparison
TPVG vs FENC Comparison
Compare TPVG & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPVG | FENC |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.9M | 230.8M |
| IPO Year | 2013 | 2010 |
Fundamental Metrics
Financial Performance| Metric | TPVG | FENC |
|---|---|---|
| Price | $5.57 | $9.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $5.90 | ★ $14.50 |
| AVG Volume (30 Days) | 218.4K | ★ 388.6K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 17.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.23 | 0.01 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | $7.67 | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ $24.00 | $885.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.48 | $5.65 |
| 52 Week High | $7.50 | $10.45 |
Technical Indicators
Market Signals| Indicator | TPVG | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 56.10 |
| Support Level | $5.33 | $7.40 |
| Resistance Level | $5.62 | $9.15 |
| Average True Range (ATR) | 0.14 | 0.50 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 63.29 | 34.84 |
Price Performance
Historical ComparisonAbout TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.